Antibiotic Resistance Market Size, Share & Trends Analysis Report By Disease (BSI, CDI, cUTI, cIAI), By Pathogen (E. coli, P. Aeruginosa, K. Pneumoniae), By Drug Class, and Segment Forecasts, 2018 - 2025

Table of Contents

Chapter 1 Report Scope
1.1 Segment Market Scope
1.2 Regional Scope
1.3 Estimates & Forecast Timeline
Chapter 2 Research Methodology
2.1 Model Details
2.1.1 Regression and variable analysis
2.2 Information Procurement
2.2.1 List of secondary sources
2.3 List of Primary Sources
2.4 Purchased database:
2.5 GVR’s internal database
2.6 Primary interview breakup
2.6.1 Data for primary interviews, by sources
2.6.2 Data for primary interviews, by region
Chapter 3 Report Objectives
3.1 Objectives
Chapter 4 Executive Summary
4.1 Market Summary
4.2 Porter’s five forces analysis
Chapter 5 Market Definitions
Chapter 6 Industry Outlook
6.1 Business Segment Trend Analysis
6.2 Pricing Analysis
6.3 Market Variable Analysis
6.3.1 Market Driver Analysis
6.3.1.1 High burden of antibiotic-resitant pathogens generates demand for new antibiotics
6.3.1.2 Increase in global initiatives to control drug-resistance
6.3.2 Market Restraints Analysis
6.3.2.1 High treatment costs
6.4 Business Environment Analysis Tools
6.4.1 Antibiotic resistance market - SWOT analysis, by factor (political & legal, economic and technological)
6.4.2 Penetration & growth prospect mapping by disease, 2017
Chapter 7 Regulatory Landscape
7.1 U.S.
7.2 Canada
7.3 Europe
7.4 Asia Pacific
7.5 Latin America
Chapter 8 Competitive & Vendor Landscape
8.1 Market Participation Categorization
8.1.1 Market leader
8.1.2 Innovators
8.2 Strategic Initiatives & Outcome Analysis
8.3 Company Market Share Analysis
8.3.1 Antibiotic resistance company market share analysis, 2014 & 2025
Chapter 9 Antibiotic Resistance Market: Disease Analysis
9.1 Disease Type Business Analysis
9.1.1 Clostridium difficile infections (CDI)
9.1.1.1 CDI market estimates and forecasts, 2014 - 2025 (USD Million)
9.1.2 Complicated Intra Abdominal Infections (cIAI)
9.1.2.1 cIAI market estimates and forecasts, 2014 - 2025 (USD Million)
9.1.3 Acute bacterial skin and skin structure infections (ABSSSI)
9.1.3.1 ABSSSI estimates and forecasts, 2014 - 2025 (USD Million)
9.1.4 Hospital acquired bacterial pneumonia/ventilator associated bacterial pneumonia (HABP/VABP)
9.1.4.1 HABP/VABP estimates and forecasts, 2014 - 2025 (USD Million)
9.1.5 Community Acquired Bacterial Pneumonia (CABP)
9.1.5.1 CABP estimates and forecasts, 2014 - 2025 (USD Million)
9.1.6 Complicated urinary tract infections (cUTI)
9.1.6.1 cUTI estimates and forecasts, 2014 - 2025 (USD Million)
9.1.7 Bloodstream Infections (BSI)
9.1.7.1 BSI estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 10 Antibiotic Resistance Market: Pathogen Type Analysis
10.1 Pathogen Type Business Analysis
10.1.1 Acinetobacter baumannii (Carbapenem-Resistant)
10.1.1.1 Acinetobacter baumannii market estimates and forecasts, 2014 - 2025 (USD Million)
10.1.2 Staphylococcus Aureus (Methicillin-Resistant)
10.1.2.1 Staphylococcus Aureus (Methicillin-Resistant) market estimates and forecasts, 2014 - 2025 (USD Million)
10.1.3 Pseudomonas aeruginosa (Carbapenem-Resistant)
10.1.3.1 Pseudomonas aeruginosa market estimates and forecasts, 2014 - 2025 (USD Million)
10.1.4 E. coli/K. pneumoniae (Carbapenem-Resistant)
10.1.4.1 E. coli/K. pneumoniae market estimates and forecasts, 2014 - 2025 (USD Million)
10.1.5 Enterococcus faecium (Vancomycin-Resistant)
10.1.5.1 Enterococcus faecium market estimates and forecasts, 2014 - 2025 (USD Million)
10.1.6 Streptococcus pneumoniae (Penicillin-Non-Susceptible)
10.1.6.1 Streptococcus pneumoniae market estimates and forecasts, 2014 - 2025 (USD Million)
10.1.7 Haemophilus influenzae (Ampicillin-Resistant)
市场估计10.1.7.1流感嗜血杆菌nd forecasts, 2014 - 2025 (USD Million)
10.1.8 Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
10.1.8.1 Clostridium difficile market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 11 Antibiotic Resistance Market: Drug Class Analysis
11.1 Drug Class Business Analysis
11.1.1 Tetracyclines
11.1.1.1 Tetracyclines market estimates and forecasts, 2014 - 2025 (USD Million)
11.1.2 Oxazolidinones
11.1.2.1 Oxazolidinones market estimates and forecasts, 2014 - 2025 (USD Million)
11.1.3 Lipoglycopeptides/glycopeptides
11.1.3.1 Lipoglycopeptides/Glycopeptides market estimates and forecasts, 2014 - 2025 (USD Million)
11.1.4 Cephalosporins
11.1.4.1 Cephalospirins market estimates and forecasts, 2014 - 2025 (USD Million)
11.1.5 Combination therapies
11.1.5.1 combination therpaies market estimates and forecasts, 2014 - 2025 (USD Million)
11.1.6 Others
11.1.6.1 Others therpaies market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 12 Antibiotic resistance Market: Regional Analysis
12.1 North America
12.1.1 North America Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.1.2 U.S.
12.1.2.1 U.S. Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.1.3 Canada
12.1.3.1 Canada Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.2 Europe
12.2.1 Europe Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.2.2 U.K.
12.2.2.1 U.K. Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.2.3 Germany
12.2.3.1 Germany Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.2.4 France
12.2.4.1 France Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.2.5 Italy
12.2.5.1 Italy Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.2.6 Spain
12.2.6.1 Spain Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.2.7 Belgium
12.2.7.1 Belgium Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.2.8 Greece
12.2.8.1 Greece Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.2.9 Portugal
12.2.9.1 Portugal Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.3 Asia Pacific
12.3.1 Asia Pacific Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.3.2 Japan
12.3.2.1 Japan Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.3.3 China
12.3.3.1 China Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.3.4 India
12.3.4.1 India Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.3.5 South Korea
12.3.5.1 Korea Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.3.6 Australia
12.3.6.1 Australia Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.3.7 Hong kong
12.3.7.1 Hong Kong Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.3.8 Singapore
12.3.8.1 Singapore Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.3.9 Taiwan
12.3.9.1 Taiwan Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.4 Latin America
12.4.1 Latin America Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.4.2 Brazil
12.4.2.1 Brazil Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.4.3 Mexico
12.4.3.1 Mexico Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.4.4 Argentina
12.4.4.1 Argentina Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.5 Middle East and Africa
12.5.1意味着抗生素耐药性的市场预期and forecasts, 2014 - 2025 (USD Million)
12.5.2 South Africa
12.5.2.1 South Africa Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.5.3 Saudi Arabia
12.5.3.1 Saudi Arabia Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.5.4 Turkey
12.5.4.1 Turkey Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
12.5.5 U.A.E.
12.5.5.1 U.A.E. Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 13 Company Profiles
13.1 Key Company Profiled
13.1.1 Achaogen, Inc.
13.1.1.1 Company overview
13.1.1.2 Financial performance
13.1.1.3 Product overview
13.1.1.4 Regulatory developments
13.1.1.5 Product pipeline
13.1.1.6 Business strategies
13.1.1.7 SWOT analysis
13.1.2 Basilea Pharmaceutica Ltd.
13.1.2.1 Company Overview
13.1.2.2 Financial Performance
13.1.2.3 Product Overview
13.1.2.4 Regulatory Developments
13.1.2.5 Product Pipeline
13.1.2.6 Business Strategies
13.1.2.7 SWOT Analysis
13.1.3 Melinta Therapeutics
13.1.3.1 Company Overview
13.1.3.2 Financial Performance
13.1.3.3 Product Overview
13.1.3.4 Regulatory Developments
13.1.3.5 Product Pipeline
13.1.3.6 Business Strategies
13.1.3.7 SWOT Analysis
13.1.4 Tetraphase Pharmaceuticals, Inc.
13.1.4.1 Company Overview
13.1.4.2 Financial Performance
13.1.4.3 Product Overview
13.1.4.4 Regulatory Developments
13.1.4.5 Product pipeline
13.1.4.6 Business strategies
13.1.4.7 SWOT analysis
13.1.5 Theravance Biopharma, Inc.
13.1.5.1 Company overview
13.1.5.2 Financial performance
13.1.5.3 Product overview
13.1.5.4 Regulatory Developments
13.1.5.5 Product pipeline
13.1.5.6 Business strategies
13.1.5.7 Swot analysis
13.1.6 Wockhardt therapeutics
13.1.6.1 Company overview
13.1.6.2 Product overview
13.1.6.3 Clinical trials
13.1.6.4 SWOT analysis
13.1.7 Entasis Therapeutics
13.1.7.1 Company overview
13.1.7.2 Product overview
13.1.7.3 Clinical trials
13.1.7.4 SWOT analysis
13.1.8 PARATEK therapeutics
13.1.8.1 Company overview
13.1.8.2 Product overview
13.1.8.3 Clinical trials
13.1.8.4 SWOT analysis
13.1.9 Seres Therapeutics, Inc.
13.1.9.1 Company overview
13.1.9.2 Product overview
13.1.9.3 Clinical trials
13.1.9.4 SWOT analysis
Chapter 14 Pipeline Analysis
14.1临床管道活动
14.2 Promising therapies - By Disease
14.2.1 ABSSSI
14.2.2 Pneumonia (CABP/HABP/VABP)
14.2.3 CABP
14.2.4 HABP/VABP
14.2.5 cIAI
14.2.6 cUTI
14.3 Promising therapies - By pathogen
14.3.1 Staphlococcus Aureus (Methicillin resistant)
14.3.2 Enterobacteriaceae (Carbapenem resistant)
14.4 Potential breakthrough drugs

List of Tables

Table 1 List of Abbreviations
Table 2 Country share estimation

List of Figures

Fig. 1 Market segmentation
Fig. 2 Market research process
Fig. 3 Value chain-based sizing & forecasting
Fig. 4 QFD modelling for market share assessment
Fig. 5 Information procurement
Fig. 6 Primary interviews, by sources
Fig. 7 Primary interviews, by region
Fig. 8 Porter’s Five Forces Analysis
Fig. 9 Antibiotic resistance market revenues, 2017, (USD Millions)
Fig. 10 Market trends & outlook
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 Market restraints relevance analysis (Current & future impact)
Fig. 13 Antibiotic resistance - SWOT analysis, by factor (political & legal, economic and technological)
Fig. 14 Penetration &growth prospect mapping by disease, 2017
Fig. 15 Strategy framework analysis, 2017
Fig. 16 Antibiotic resistance company market share(%), 2017
Fig. 17 Antibiotic resistance market disease outlook: Key takeaways
Fig. 18 Antibiotic resistance market: Disease movement analysis
Fig. 19 Global CDI market, 2014 - 2025 (USD Million)
Fig. 20 Global cIAI market, 2014 - 2025 (USD Million)
Fig. 21 Global ABSSSI market, 2014 - 2025 (USD Million)
Fig. 22 Global HABP/VABP market, 2014 - 2025 (USD Million)
Fig. 23 Global CABP market, 2014 - 2025 (USD Million)
Fig. 24 Global cUTI market, 2014 - 2025 (USD Million)
Fig. 25 Antibiotic resistance market, Pathogen type: Key takeaways
Fig. 26 Antibiotic resistance market: Pathogen movement analysis
Fig. 27 Global A. baumannii surgery market, 2014 - 2025 (USD Million)
Fig. 28 Global S aureus market, 2014 - 2025 (USD Million)
Fig. 29 Global P. aeruginosa market, 2014 - 2025 (USD Million)
Fig. 30 Global E. coli/K. pneumoniae market, 2014 - 2025 (USD Million)
图31全球肠球菌都有效市场,2014年2025 (USD Million)
Fig. 32 Global Streptococcus pneumoniae market, 2014 - 2025 (USD Million)
Fig. 33 Global H. influenza market, 2014 - 2025 (USD Million)
Fig. 34 Global C. difficile market, 2014 - 2025 (USD Million)
Fig. 35 Antibiotic resistance market end use outlook: Key takeaways
Fig. 36 Antibiotic resistance market: End use movement analysis
Fig. 37 Global Tetracyclines market, 2014 - 2025 (USD Million)
Fig. 38 Global Oxazolidinones market, 2014 - 2025 (USD Million)
Fig. 39 Global lipoglycopeptides/glycopeptides market, 2014 - 2025 (USD Million)
Fig. 40 Global Cephalosporins market, 2014 - 2025 (USD Million)
Fig. 41 Global combination therapy market, 2014 - 2025 (USD Million)
Fig. 42 Global other therapy market, 2014 - 2025 (USD Million)
Fig. 43 Regional market place: Key takeaways
Fig. 44 Regional outlook, 2014 - 2025 (USD Million)
Fig. 45 North America Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 46 U.S. Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 47 Canada Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 48 Europe Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 49 U.K. Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 50 Germany Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 51 France Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 52 Italy Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 53 Spain Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 54 Belgium Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 55 Greece Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 56 Portugal Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 57 Asia Pacific Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 58 Japan Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 59 China Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 60 India Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 61 Korea Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 62 Australia Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 63 Hong Kong Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 64 Singapore Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 65 Taiwan Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 66 Latin America Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 67 Brazil Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 68 Mexico Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 69 Argentina Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 70 MEA Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 71 South Africa Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 72 Saudi Arabia Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 73 Turkey Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 74 U.A.E. Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 75 Achaogen, Inc. - SWOT analysis
Fig. 76 Basilea Pharmaceutica - SWOT analysis
Fig. 77 Melinta - SWOT analysis
Fig. 78 Tetraphase Pharmaceuticals - SWOT analysis
Fig. 79 Theravance Biopharma - SWOT analysis
Fig. 80 Nabriva Therapeutics - SWOT analysis
Fig. 81 Nabriva Therapeutics - SWOT analysis
Fig. 82 Paratek Therapeutics - SWOT analysis
Fig. 83 Seres Therapeutics, Inc. - SWOT analysis
Fig. 84 Pipeline Therapies
Fig. 85 Promising Therapies